NFKBIZ

Across TCGA pan-cancer cohorts, NFKBIZ Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NFKBIZ data layer compared with 26 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher NFKBIZ Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NFKBIZ expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and PRAD are the cancer types where NFKBIZ Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.362	0.842	.005	18	view →
UCEC	DFS	Median	All	0.841	0.631	.013	16	view →
PRAD	DFS	Median	All	0.085	0.776	<.001	12	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	12	view →
LIHC	OS	Median	All	0.144	0.688	.014	9	view →
KIRC	OS	Median	All	0.151	0.628	.045	6	view →
SKCM	OS	Median	All	0.560	0.872	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NFKBIZ–OV (OS)

Open the OV breakdown →